Get the Latest Scientific News
Sign up for latest scientific news and use cases in biomedical research.
News & Updates
FINBB Announces a Collaboration with aiwell Inc. to Identify New Biomarkers
Finnish Biobanks – FINBB has entered a new partnership with aiwell Inc., a company focused on AI proteomics and headquartered in Tokyo, Japan. aiwell Inc.'s goal is to identify new biomarkers for various diseases, such as depression and cancer.
Event: Fingenious Ecosystem Offers More, Tuesday 14 June 2022
The event offers for the very first time an opportunity to get acquainted with what Finland has to offer for biomedical research as a One-stop-Service.
Rare Diseases Affect Millions of Lives Around the World
A serious or life-threatening rare disease affect more than 300 million people around the world. Approximately 7,000 rare diseases have been identified worldwide, but treatments are available for just over a hundred of them.
Fingenious® Serves Researchers in Three Steps
Browse biobank collections
By registering you can access the free electronic Fingenious® ICD-10 Catalogue to browse biobank sample and data collections at aggregate-level.
Sample and data availability
After registering fill in Fingenious® Feasibility request to obtain more detailed information about the sample and data availability at Finnish biobanks.
Access samples and data
Proceed to Fingenious® Access request: one centralized service for an access to Finnish public biobanks requiring just one contract for the researcher.
Biobank Collections and Services
You can access the Finnish public biobanks through Fingenious®portal:
Access to >11 million samples consisting of blood, FFPE and DNA samples, fresh frozen tissue and liquid biopsies.
Phenotype data, such as clinical health record data, can be provided together with the samples.
The genetic data analyzed in biobank studies, such as FinnGen, is returned to and available at the biobanks.
Finding study participants
Possibility to recontact consented sample donors via biobanks for further biomedical studies.
Breakthroughs in disease prevention, diagnosis and treatment
Why Choose Finland for Your Biomedical Research?
Well-functioning healthcare system
The entire population is covered with longitudinal electronic health records and a personal identification code that enables linking of the biobank samples to deep phenotypic data.
World-class genomic data
The FinnGen research project produces genotype data returning back to the biobanks where it can be combined with deep phenotypic data.
Research-advancing Biobank Act has been in force since 2013. Act on the Secondary Use of Health and Social Data has been in force since May 2019 and a proposal for the Genome Act is in preparation.
A national commitment
Finnish government drives innovation in personalized medicine, with a biobank ecosystem at its core.
Finns trust researchers and are willing to participate in public screening programs and donate
their samples to biobanks.
Study participant finding
Sample donors with a prior consent can be contacted for further biomedical studies.